Key result
A review of clinical and experimental studies on renal denervation highlights inconsistent results, such as the Symplicity-III trial showing no significant BP reduction at 6 months versus controls.
Why the study?
Does renal denervation reduce blood pressure in patients with resistant hypertension?
Does renal denervation reduce blood pressure in patients with resistant hypertension?
This review explores the basic science and clinical trial designs to understand the inconsistent efficacy results of renal denervation for resistant hypertension.
Answers are grounded in this paper and cite their sources.
Inconsistent renal denervation results advise against routine use in resistant hypertension; leaves open need for standardized trials.
Hypertension poses growing challenge for health policy-makers and doctors worldwide. Recently published results of Symplicity-III trial (HTN-3), the first blinded, randomized, multicenter study on the efficacy of renal denervation for the treatment of resistant hypertension did not show a significant reduction of BP in patients with resistant hypertension 6 months after renal-artery denervation, as compared with controls. In this paper we review clinical and experimental studies on renal denervation. In order to identify causes of inconsistent results in renal denervation studies we look at basic science support for renal denervation and at designs of clinical trials.
No takes yet. Share an insight, caveat, or question.
Skrzypecki et al. (2015) conducted a review in resistant hypertension. renal denervation vs. controls was evaluated on reduction of BP. A review of clinical and experimental studies on renal denervation highlights inconsistent results, such as the Symplicity-III trial showing no significant BP reduction at 6 months versus controls.
Synapse has enriched 10 related papers. Consider them for comparative context: